501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers

BACKGROUND: Bezlotoxumab (BEZ) was approved in October 2016 for the prevention of recurrent C. difficile (rCDI) infection in patients receiving standard-of-care (SoC) antibiotic therapy for active CDI who are at high risk for CDI recurrence. Presently, there are little real-world data on recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Hengel, Richard L, Ritter, Timothy E, Nathan, Ramesh V, Anglen, Lucinda J Van, Schroeder, Claudia P, Marcella, Stephen, Garey, Kevin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253562/
http://dx.doi.org/10.1093/ofid/ofy210.510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253562/
http://dx.doi.org/10.1093/ofid/ofy210.510

Ejemplares similares